Reaction
Pulmonary Sarcoidosis reporting signals
As of the last recalculation, Pulmonary Sarcoidosis appears in 1,092 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-FKJP (PRR 22.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Fkjp | 52 | 22.4 | 22.4 |
| Adalimumab-Aaty | 52 | 21.9 | 22.0 |
| Adalimumab-Adaz | 52 | 19.7 | 19.7 |
| Ipilimumab | 23 | 10.4 | 10.4 |
| Pembrolizumab | 49 | 9.2 | 9.3 |
| Panitumumab | 7 | 8.6 | 8.6 |
| Paclitaxel (Aibumin-Bound) | 32 | 7.6 | 7.6 |
| Nivolumab | 35 | 7.1 | 7.1 |
| Peginterferon Alfa-2A | 16 | 5.7 | 5.7 |
| Certolizumab Pegol | 34 | 5.7 | 5.7 |